Proteonomix, Inc., (OTCBB: PROT) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.
Proteoderm, Inc. a wholly owned subsidiary of PROT that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (NYSE:CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is PROT’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine.
PROT intends to create and dedicate a subsidiary to each of its technologies.
** PROT has filed a utility patent application for the Preparation and Use of Stromal Cells for Treatment of Cardiac Diseases.
This is another step in the development of PROT’s intellectual property and getting StromaCel into the commercial market.
The technology covered by the patent application will reduce the cost to the patient of this type of treatment and when trials are completed and regulatory approvals are obtained PROT believes that the stromal cell technology will have major importance in the treatment of cardiac damage caused by heart attacks.
Without going into proprietary details, Mr. Cohen, President of PROT noted that the application relates to cell line expansion that he believes represents a fundamental improvement in the efficiency of producing stem cells which should have applications far beyond the cardiac therapy to which the present application relates.
More about PROT at www.proteonomix.com
LCA-Vision Inc. (Nasdaq:LCAV), a leading provider of laser vision correction services under the LasikPlus® brand, recently reported that 11,497 procedures were performed during the third quarter of 2010.
This compares with 15,335 procedures (71 vision centers) and 14,068 same-store procedures (62 vision centers) performed during the third quarter of 2009.
LDK Solar Co., Ltd. (NYSE:LDK), a leading manufacturer of multicrystalline solar wafers and PV products, recently provided an updated outlook for its third quarter 2010 financial results.
For the third quarter of 2010, LDK expects to report revenue in the range of $610 to $640 million, wafer shipments of 550 to 570 megawatts (MW), and module shipments of 80 MW to 90 MW.
LDK's prior guidance for the third quarter was revenue of $570 to $600 million, wafer shipments of 520 to 550 MW, and module shipments of 75 to 85 MW.
Leading Brands, Inc. (Nasdaq:LBIX), North America's only fully integrated healthy branded beverage company, recently reported results for the second quarter of its 2010 fiscal year, which ended August 31, 2010. All financial amounts are denominated in Canadian dollars.
Q2 net income before stock based compensation (SBC) was $632,000 or $0.16 per share versus $876,000 or $0.22 per share in the same quarter last year. Year to date net income before SBC was $1,110,000 or $0.28 per share as compared to $1,151,000 or $0.28 in the same period of fiscal 2009. Q2 net loss including SBC was $549,000 or $0.14 per share versus a net income including SBC of $809,000 or $0.20 per share in the same quarter of fiscal 2009.
Leap Wireless International, Inc. (NASDAQ:LEAP), a leading provider of innovative and value-driven wireless communications services, and Pocket Communications, recently reported they have formed a Leap-controlled and managed joint venture that provides enhanced mobile communications through LEAPs Cricket® brand to customers in the South Texas region, from San Antonio to Laredo and in the Rio Grande Valley covering more than 4.4 million potential customers.
The agreement to form the joint venture was announced February 23, 2010.
Signup for FREE Daily Stock Alerts From http://www.CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT).